Your browser doesn't support javascript.
loading
Population-level viremia predicts HIV incidence at the community level across the Universal Testing and Treatment Trials in eastern and southern Africa.
Larmarange, Joseph; Bachanas, Pamela; Skalland, Timothy; Balzer, Laura B; Iwuji, Collins; Floyd, Sian; Mills, Lisa A; Pillay, Deenan; Havlir, Diane; Kamya, Moses R; Ayles, Helen; Wirth, Kathleen; Dabis, François; Hayes, Richard; Petersen, Maya.
Afiliação
  • Larmarange J; Centre Population et Développement, Université Paris Cité, IRD, Inserm, Paris, France.
  • Bachanas P; Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
  • Skalland T; Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
  • Balzer LB; Division of Biostatistics, School of Public Health, University of California, Berkeley, California, United States of America.
  • Iwuji C; Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, United Kingdom.
  • Floyd S; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Mills LA; Division of Global HIV and TB, Centers for Disease Control and Prevention, Gaborone, Botswana.
  • Pillay D; Division of Infection & Immunity, University College London, London, United Kingdom.
  • Havlir D; Department of Medicine, University of California San Francisco, San Francisco, CA, United States of America.
  • Kamya MR; Department of Medicine, Makerere University Kampala, Uganda and the Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Ayles H; Clinical Research Department London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Wirth K; Zambart, University of Zambia School of Public Health, Lusaka, Zambia.
  • Dabis F; Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
  • Hayes R; Université Bordeaux, ISPED, Centre INSERM U1219-Bordeaux Population Health, Bordeaux, France.
  • Petersen M; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLOS Glob Public Health ; 3(7): e0002157, 2023.
Article em En | MEDLINE | ID: mdl-37450436
ABSTRACT
Universal HIV testing and treatment (UTT) strategies aim to optimize population-level benefits of antiretroviral treatment. Between 2012 and 2018, four large community randomized trials were conducted in eastern and southern Africa. While their results were broadly consistent showing decreased population-level viremia reduces HIV incidence, it remains unclear how much HIV incidence can be reduced by increasing suppression among people living with HIV (PLHIV). We conducted a pooled analysis across the four UTT trials. Leveraging data from 105 communities in five countries, we evaluated the linear relationship between i) population-level viremia (prevalence of non-suppression-defined as plasma HIV RNA >500 or >400 copies/mL-among all adults, irrespective of HIV status) and HIV incidence; and ii) prevalence of non-suppression among PLHIV and HIV incidence, using parametric g-computation. HIV prevalence, measured in 257 929 persons, varied from 2 to 41% across the communities; prevalence of non-suppression among PLHIV, measured in 31 377 persons, from 3 to 70%; population-level viremia, derived from HIV prevalence and non-suppression, from < 1% to 25%; and HIV incidence, measured over 345 844 person-years (PY), from 0.03/100PY to 3.46/100PY. Decreases in population-level viremia were strongly associated with decreased HIV incidence in all trials (between 0.45/100PY and 1.88/100PY decline in HIV incidence per 10 percentage points decline in viremia). Decreases in non-suppression among PLHIV were also associated with decreased HIV incidence in all trials (between 0.06/100PY and 0.17/100PY decline in HIV incidence per 10 percentage points decline in non-suppression). Our results support both the utility of population-level viremia as a predictor of incidence, and thus a tool for targeting prevention interventions, and the ability of UTT approaches to reduce HIV incidence by increasing viral suppression. Implementation of universal HIV testing approaches, coupled with interventions to leverage linkage to treatment, adapted to local contexts, can reduce HIV acquisition at population level.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article